Tune in to this new episode of MAP to explore New Zealand’s unique healthcare and reimbursement landscape with Dr. Stefan Walzer and health economist Dr. Julius Ohnberger. Learn how PHARMAC combines HTA and payer roles, why equity and Māori health outcomes are central to market access and what global pharma can gain from launching in Aotearoa.
Key insights include why New Zealand’s HTA model stands out as a global unicorn, how to navigate cultural and equity requirements in submissions, the importance of local evidence and stakeholder engagement, the impact of budget constraints and the shift toward real‑world data and outcome‑based reimbursement, and why the country may be the ideal testbed for innovations in AI, screening, and chronic care. Essential for professionals in pricing, market access, and global health policy.
